<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404989</url>
  </required_header>
  <id_info>
    <org_study_id>APR</org_study_id>
    <nct_id>NCT00404989</nct_id>
  </id_info>
  <brief_title>Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.</brief_title>
  <acronym>APR</acronym>
  <official_title>Antiretroviral Pregnancy Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apotex Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aurobindo Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cipla Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hetero Labs Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Scientific Affairs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lupin Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prinston Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ranbaxy Inc., a SunPharma Co.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sciegen Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sigmapharm Laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silarx Pharmaceuticals Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Strides Shasun Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alvogen Korea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>West-Ward Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Reddy's Laboratories UK Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentiva Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>INC Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major
      teratogenic effect involving any of the Registry drugs when administered to pregnant women.
      Registration is voluntary and confidential with information obtained from the health care
      provider. A Registry-assigned identifier allows for follow-up capability. Information on
      subjects is provided to the Registry prospectively (prior to the outcome of pregnancy being
      known) through their health care provider, with follow-up obtained from the health care
      provider after the outcome is determined. Providers are strongly urged to enroll their
      patients as early in pregnancy as possible to maximize the validity of the data. In addition,
      the Registry is very interested in assembling a group of providers who are willing to make a
      commitment to report all of their site's antiretroviral pregnancy exposures to the Registry,
      thereby assuring all cases can be considered prospective. Providers are encouraged to contact
      the Registry for more information about this group. The Registry is informed in its analysis
      by other data, for example, retrospective reports and clinical studies.

      Given the increasing number of medications and more aggressive approach to therapy, more HIV-
      and hepatitis B-infected women may be treated during pregnancy or become pregnant while under
      treatment. The paucity of data on use and infant outcomes of antiretroviral therapies during
      pregnancy makes this Registry an essential component of the ongoing program of epidemiologic
      studies of the safety of these therapies.

      Each year the Registry has enrolled approximately 1300 pregnant women in the US exposed to
      antiretroviral drugs. This number represents approximately 15% of the 8,700 HIV positive
      women who give birth to live infants annually in the US.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following antiretroviral drugs are followed by the Antiretroviral Pregnancy Registry
      (APR: Registry) to detect any major teratogenic effect when administered to pregnant women:
      abacavir (ZIAGEN®, ABC), abacavir/lamivudine combination (EPZICOM®, EPZ),
      abacavir/lamivudine/zidovudine combination (TRIZIVIR®, TZV), abacavir/dolutegravir/lamivudine
      combination (TRIUMEQ®, TRI), adefovir dipivoxil (HEPSERA®, ADV), amprenavir (AGENERASE®,
      APV), atazanavir (REYATAZ®, ATV), atazanavir/cobicistat combination (EVOTAZ®, EVO),
      cobicistat (TYBOST®, COBI), darunavir (PREZISTA®, DRV), darunavir/cobicistat combination
      (PREZCOBIX™, REZOLSTA™, PCX), delavirdine mesylate (RESCRIPTOR®, DLV), didanosine (VIDEX®,
      VIDEX® EC, ddI), dolutegravir (TIVICAY®, DTG), emtricitabine/ tenofovir alafenamide
      (DESCOVY®,DVY) efavirenz (SUSTIVA®, STOCRIN®, EFV), efavirenz/emtricitabine/ tenofovir
      disoproxil combination (ATRIPLA® ATR), elvitegravir (VITEKTA®, EVG),
      elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination (GENVOYA®, GEN),
      elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination (STRIBILD®,
      STB), emtricitabine (EMTRIVA®, FTC), enfuvirtide (FUZEON®, T-20), entecavir (BARACLUDE®,
      ETV), etravirine (INTELENCE®, ETR), fosamprenavir calcium (LEXIVA®, FOS), indinavir
      (CRIXIVAN®, IDV), lamivudine (EPIVIR®, 3TC), lamivudine/raltegravir combination (DUTREBIS™,
      DUT), lamivudine/zidovudine combination (COMBIVIR®, ZDV+3TC), lopinavir/ritonavir combination
      (KALETRA®, ALUVIA®, LPV/r), maraviroc (SELZENTRY®, CELSENTRI®, MVC), nelfinavir (VIRACEPT®,
      NFV), nevirapine (VIRAMUNE®, VIRAMUNE® XR™, NVP), raltegravir (ISENTRESS®, RAL), rilpivirine
      (EDURANT®, RPV), rilpivirine/emtricitabine/tenofovir alafenamide (GENVOYA®,GEN)
      rilpivirine/emtricitabine/tenofovir disoproxil combination (COMPLERA®, CPA; EVIPLERA®, EPA),
      ritonavir (NORVIR®, RTV), saquinavir (FORTOVASE®, SQV-SGC), saquinavir mesylate (INVIRASE®,
      SQV-HGC), stavudine (ZERIT®, d4T), telbivudine (SEBIVO®, TYZEKA®, LdT), tenofovir alafenamide
      (VEMLIDY®, TAF), tenofovir disoproxil fumarate (VIREAD®, TDF), tenofovir disoproxil fumarate
      /emtricitabine (TRUVADA®, TVD), tipranavir (APTIVUS®, TPV), zalcitabine (HIVID®, ddC), and
      zidovudine (RETROVIR®, ZDV). Zidovudine is indicated for use in the second and third
      trimesters of pregnancy to reduce the risk of maternal-fetal HIV transmission. There are also
      several other completed and ongoing studies in maternal-fetal transmission with other
      therapies. However, the safety of prenatal zidovudine or any other antiretroviral therapy
      exposure to the fetus has not been established.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 1989</start_date>
  <completion_date type="Anticipated">January 2099</completion_date>
  <primary_completion_date type="Anticipated">January 2099</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women exposed to antiviral medications during pregnancy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Ages Eligible for Study: Women of childbearing age

        Inclusion Criteria:

          -  Country of origin of report

          -  Documentation that the registry drug was taken during pregnancy

          -  Sufficient information to determine if the pregnancy is being prospectively or
             retrospectively registered

          -  Date the pregnancy was registered

          -  Source of report (patient or health care provider)

          -  Whether the pregnancy outcome is already known or delivery is still pending

          -  Timing of the prenatal exposure to the registry medication (no broader than which
             trimester)

          -  Sufficient patient identifier relevant to reporter to allow for follow-up

          -  Was patient involved in a study at the time of prenatal exposure

          -  Full reporter contact information (name, address, etc.)

        Exclusion Criteria:

          -  Females who were not exposed to registry medications during pregnancy

          -  Male patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica D Albano, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>INC Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Goodlow</last_name>
    <phone>800-258-4263</phone>
    <email>SM_APR@INCResearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Taylor Cook</last_name>
    <phone>800-258-4263</phone>
    <email>SM_APR@INCResearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Registry Coordinating Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://apregistry.com</url>
    <description>Download: data forms to register patients, Semi-Annual Interim Report, product package inserts, organizational links, guidelines, bibliography</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

